Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01130272
Other study ID # 27018966IBS2001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 28, 2010
Est. completion date July 14, 2011

Study information

Verified date September 2019
Source Furiex Pharmaceuticals, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).


Recruitment information / eligibility

Status Completed
Enrollment 807
Est. completion date July 14, 2011
Est. primary completion date July 14, 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Key Inclusion Criteria:

- Patient has a diagnosis of IBS by Rome III criteria with a subtype of diarrhea

- Female patients must be:

- postmenopausal, defined as amenorrhea for at least 2 years at Prescreening,

- surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),

- abstinent, or

- if sexually active, be practicing an effective method of birth control.

Key Exclusion Criteria:

- Patient has a diagnosis of IBS by Rome III criteria with a subtype of constipation, mixed IBS, or unsubtyped IBS

- Patient has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease

- Patient has a history of diverticulitis within 6 months prior to Prescreening

- Patient has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, impaired intestinal circulation (eg, aortoiliac disease), thrombophlebitis of a major vein, or hypercoagulable states.

Other protocol-specific eligibility criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Eluxadoline
Tablets, orally, twice daily.
Placebo
Matching placebo oral tablets twice daily.

Locations

Country Name City State
United States Furiex Research Site Akron Ohio
United States Furiex Research Site Albuquerque New Mexico
United States Furiex Research Site Albuquerque New Mexico
United States Furiex Research Site Alexandria Virginia
United States Furiex Research Site Aliso Viejo California
United States Furiex Research Site Anaheim California
United States Furiex Research Site Anderson Indiana
United States Furiex Research Site Anderson South Carolina
United States Furiex Research Site Annapolis Maryland
United States Furiex Research Site Anniston Alabama
United States Furiex Research Site Atco New Jersey
United States Furiex Research Site Atlanta Georgia
United States Furiex Research Site Atlanta Georgia
United States Furiex Research Site Austin Texas
United States Furiex Research Site Aventura Florida
United States Furiex Research Site Azusa California
United States Furiex Research Site Beachwood Ohio
United States Furiex Research Site Beavercreek Ohio
United States Furiex Research Site Bedford Texas
United States Furiex Research Site Bellevue Nebraska
United States Furiex Research Site Billings Montana
United States Furiex Research Site Binghamton New York
United States Furiex Research Site Birmingham Alabama
United States Furiex Research Site Birmingham Alabama
United States Furiex Research Site Blackwood New Jersey
United States Furiex Research Site Bloomington Indiana
United States Furiex Research Site Boca Raton Florida
United States Furiex Research Site Boca Raton Florida
United States Furiex Research Site Boise Idaho
United States Furiex Research Site Boise Idaho
United States Furiex Research Site Boone North Carolina
United States Furiex Research Site Boston Massachusetts
United States Furiex Research Site Boston Massachusetts
United States Furiex Research Site Boston Massachusetts
United States Furiex Research Site Bowling Green Kentucky
United States Furiex Research Site Bozeman Montana
United States Furiex Research Site Bradenton Florida
United States Furiex Research Site Brandon Florida
United States Furiex Research Site Bristol Connecticut
United States Furiex Research Site Bristol Tennessee
United States Furiex Research Site Brockton Massachusetts
United States Furiex Research Site Brooklyn New York
United States Furiex Research Site Brooklyn New York
United States Furiex Research Site Burbank California
United States Furiex Research Site Carlsbad California
United States Furiex Research Site Champaign Illinois
United States Furiex Research Site Chandler Arizona
United States Furiex Research Site Chapel Hill North Carolina
United States Furiex Research Site Charlotte North Carolina
United States Furiex Research Site Charlotte North Carolina
United States Furiex Research Site Chaska Minnesota
United States Furiex Research Site Chattanooga Tennessee
United States Furiex Research Site Chattanooga Tennessee
United States Furiex Research Site Chesapeake Virginia
United States Furiex Research Site Chesterfield Michigan
United States Furiex Research Site Chevy Chase Maryland
United States Furiex Research Site Chicago Illinois
United States Furiex Research Site Chipley Florida
United States Furiex Research Site Christiansburg Virginia
United States Furiex Research Site Cincinnati Ohio
United States Furiex Research Site Cleveland Ohio
United States Furiex Research Site Colleyville Texas
United States Furiex Research Site Colorado Springs Colorado
United States Furiex Research Site Colorado Springs Colorado
United States Furiex Research Site Colorado Springs Colorado
United States Furiex Research Site Colorado Springs Colorado
United States Furiex Research Site Columbia South Carolina
United States Furiex Research Site Columbia South Carolina
United States Furiex Research Site Columbus Ohio
United States Furiex Research Site Columbus Ohio
United States Furiex Research Site Columbus Georgia
United States Furiex Research Site Cumberland Rhode Island
United States Furiex Research Site Danville Virginia
United States Furiex Research Site Dayton Ohio
United States Furiex Research Site DeLand Florida
United States Furiex Research Site Delray Beach Florida
United States Furiex Research Site Denver Colorado
United States Furiex Research Site Denver Colorado
United States Furiex Research Site Dingmans Ferry Pennsylvania
United States Furiex Research Site Doral Florida
United States Furiex Research Site Dothan Alabama
United States Furiex Research Site Duluth Georgia
United States Furiex Research Site East Providence Rhode Island
United States Furiex Research Site El Paso Texas
United States Furiex Research Site Elizabeth New Jersey
United States Furiex Research Site Encinitas California
United States Furiex Research Site Evansville Indiana
United States Furiex Research Site Fairfax Virginia
United States Furiex Research Site Fargo North Dakota
United States Furiex Research Site Fargo North Dakota
United States Furiex Research Site Fayetteville North Carolina
United States Furiex Research Site Fort Lauderdale Florida
United States Furiex Research Site Fort Worth Texas
United States Furiex Research Site Fort Worth Texas
United States Furiex Research Site Franklin Ohio
United States Furiex Research Site Garden Grove California
United States Furiex Research Site Garden Grove California
United States Furiex Research Site Germantown Tennessee
United States Furiex Research Site Glendale Arizona
United States Furiex Research Site Grand Prairie Texas
United States Furiex Research Site Grapevine Texas
United States Furiex Research Site Great Neck New York
United States Furiex Research Site Great Neck New York
United States Furiex Research Site Greensboro North Carolina
United States Furiex Research Site Greensboro North Carolina
United States Furiex Research Site Greenville North Carolina
United States Furiex Research Site Greer South Carolina
United States Furiex Research Site Harrisburg North Carolina
United States Furiex Research Site Henderson Nevada
United States Furiex Research Site Hermitage Pennsylvania
United States Furiex Research Site Hialeah Florida
United States Furiex Research Site Hialeah Florida
United States Furiex Research Site Hickory North Carolina
United States Furiex Research Site Hickory North Carolina
United States Furiex Research Site High Point North Carolina
United States Furiex Research Site Hollywood Maryland
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Houston Texas
United States Furiex Research Site Huntsville Alabama
United States Furiex Research Site Huntsville Alabama
United States Furiex Research Site Hurst Texas
United States Furiex Research Site Hyannis Massachusetts
United States Furiex Research Site Idaho Falls Idaho
United States Furiex Research Site Indianapolis Indiana
United States Furiex Research Site Indianapolis Indiana
United States Furiex Research Site Indianapolis Indiana
United States Furiex Research Site Inglewood California
United States Furiex Research Site Interlochen Michigan
United States Furiex Research Site Inverness Florida
United States Furiex Research Site Irving Texas
United States Furiex Research Site Jackson Tennessee
United States Furiex Research Site Jackson Mississippi
United States Furiex Research Site Jacksonville Florida
United States Furiex Research Site Jacksonville Florida
United States Furiex Research Site Jacksonville North Carolina
United States Furiex Research Site Jenkintown Pennsylvania
United States Furiex Research Site Johnson City Tennessee
United States Furiex Research Site Jonesboro Arkansas
United States Furiex Research Site Jupiter Florida
United States Furiex Research Site Kalamazoo Michigan
United States Furiex Research Site Kingsport Tennessee
United States Furiex Research Site Kissimmee Florida
United States Furiex Research Site Laguna Hills California
United States Furiex Research Site Lake Jackson Texas
United States Furiex Research Site Lakewood Colorado
United States Furiex Research Site Lancaster Pennsylvania
United States Furiex Research Site Lansdale Pennsylvania
United States Furiex Research Site Largo Florida
United States Furiex Research Site Las Vegas Nevada
United States Furiex Research Site Las Vegas Nevada
United States Furiex Research Site Lauderdale Lakes Florida
United States Furiex Research Site Laurel Maryland
United States Furiex Research Site Lenexa Kansas
United States Furiex Research Site Lexington Kentucky
United States Furiex Research Site Little Rock Arkansas
United States Furiex Research Site Littleton Colorado
United States Furiex Research Site Logan Utah
United States Furiex Research Site Long Beach California
United States Furiex Research Site Los Angeles California
United States Furiex Research Site Los Angeles California
United States Furiex Research Site Louisville Kentucky
United States Furiex Research Site Lutherville Maryland
United States Furiex Research Site Macon Georgia
United States Furiex Research Site Madison Wisconsin
United States Furiex Research Site Marietta Georgia
United States Furiex Research Site Marlton New Jersey
United States Furiex Research Site Marshall Texas
United States Furiex Research Site Melbourne Florida
United States Furiex Research Site Mentor Ohio
United States Furiex Research Site Meridian Idaho
United States Furiex Research Site Mesa Arizona
United States Furiex Research Site Metairie Louisiana
United States Furiex Research Site Mexico Missouri
United States Furiex Research Site Miami Florida
United States Furiex Research Site Miami Florida
United States Furiex Research Site Miami Florida
United States Furiex Research Site Miamisburg Ohio
United States Furiex Research Site Mill Creek Washington
United States Furiex Research Site Milwaukee Wisconsin
United States Furiex Research Site Mineola New York
United States Furiex Research Site Mission Kansas
United States Furiex Research Site Mobile Alabama
United States Furiex Research Site Monroe Louisiana
United States Furiex Research Site Montgomery Alabama
United States Furiex Research Site Morristown New Jersey
United States Furiex Research Site Morton Illinois
United States Furiex Research Site Mount Pleasant South Carolina
United States Furiex Research Site Murietta California
United States Furiex Research Site Nampa Idaho
United States Furiex Research Site Naples Florida
United States Furiex Research Site Naples Florida
United States Furiex Research Site Nashville Tennessee
United States Furiex Research Site Nashville Tennessee
United States Furiex Research Site New Bern North Carolina
United States Furiex Research Site New Port Richey Florida
United States Furiex Research Site New Port Richey Florida
United States Furiex Research Site New Smyrna Beach Florida
United States Furiex Research Site New York New York
United States Furiex Research Site Newnan Georgia
United States Furiex Research Site Newton Pennsylvania
United States Furiex Research Site Norman Oklahoma
United States Furiex Research Site Norman Oklahoma
United States Furiex Research Site North Richland Hills Texas
United States Furiex Research Site Novi Michigan
United States Furiex Research Site Oakland California
United States Furiex Research Site Odessa Texas
United States Furiex Research Site Ogden Utah
United States Furiex Research Site Oklahoma City Oklahoma
United States Furiex Research Site Oklahoma City Oklahoma
United States Furiex Research Site Omaha Nebraska
United States Furiex Research Site Omaha Nebraska
United States Furiex Research Site Opelousas Louisiana
United States Furiex Research Site Orange California
United States Furiex Research Site Orlando Florida
United States Furiex Research Site Overland Park Kansas
United States Furiex Research Site Overland Park Kansas
United States Furiex Research Site Pell City Alabama
United States Furiex Research Site Phoenix Arizona
United States Furiex Research Site Phoenix Arizona
United States Furiex Research Site Phoenix Arizona
United States Furiex Research Site Plano Texas
United States Furiex Research Site Plantation Florida
United States Furiex Research Site Port Orange Florida
United States Furiex Research Site Prince Frederick Maryland
United States Furiex Research Site Raleigh North Carolina
United States Furiex Research Site Raleigh North Carolina
United States Furiex Research Site Rapid City South Dakota
United States Furiex Research Site Rockville Maryland
United States Furiex Research Site Rome Georgia
United States Furiex Research Site Sacramento California
United States Furiex Research Site Saint Louis Missouri
United States Furiex Research Site Saint Peters Missouri
United States Furiex Research Site Saint Petersburg Florida
United States Furiex Research Site Salt Lake City Utah
United States Furiex Research Site Salt Lake City Utah
United States Furiex Research Site San Antonio Texas
United States Furiex Research Site San Antonio Texas
United States Furiex Research Site San Antonio Texas
United States Furiex Research Site San Antonio Texas
United States Furiex Research Site San Antonio Texas
United States Furiex Research Site San Carlos California
United States Furiex Research Site San Diego California
United States Furiex Research Site San Diego California
United States Furiex Research Site Sandy Springs Georgia
United States Furiex Research Site Savannah Georgia
United States Furiex Research Site Sayre Pennsylvania
United States Furiex Research Site Searcy Arkansas
United States Furiex Research Site Sherwood Arkansas
United States Furiex Research Site Shreveport Louisiana
United States Furiex Research Site Shreveport Louisiana
United States Furiex Research Site South Bound Brook New Jersey
United States Furiex Research Site South Jordan Utah
United States Furiex Research Site South Miami Florida
United States Furiex Research Site Springfield Massachusetts
United States Furiex Research Site Springfield Ohio
United States Furiex Research Site Sugar Land Texas
United States Furiex Research Site Sugar Land Texas
United States Furiex Research Site Tampa Florida
United States Furiex Research Site Tampa Florida
United States Furiex Research Site Tempe Arizona
United States Furiex Research Site Tempe Arizona
United States Furiex Research Site Thornton Colorado
United States Furiex Research Site Topeka Kansas
United States Furiex Research Site Troy Michigan
United States Furiex Research Site Tucson Arizona
United States Furiex Research Site Tucson Arizona
United States Furiex Research Site Tupelo Mississippi
United States Furiex Research Site Uniontown Pennsylvania
United States Furiex Research Site Vineland New Jersey
United States Furiex Research Site Virginia Beach Virginia
United States Furiex Research Site Wadsworth Ohio
United States Furiex Research Site Warwick Rhode Island
United States Furiex Research Site Washington Pennsylvania
United States Furiex Research Site Waterbury Connecticut
United States Furiex Research Site Webster Texas
United States Furiex Research Site West Jordan Utah
United States Furiex Research Site West Valley City Utah
United States Furiex Research Site Wichita Kansas
United States Furiex Research Site Wilmington North Carolina
United States Furiex Research Site Winston-Salem North Carolina
United States Furiex Research Site Winston-Salem North Carolina
United States Furiex Research Site Yukon Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Furiex Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 4 Composite responders were defined as participants who completed at least 5 out of 7 days with diary entries during the interval of interest and met both of the following criteria: 1) Average daily pain response scores over the past week improved by =30% and at least 2 points as compared with the baseline average pain score (average of daily worst abdominal pain the week prior to randomization), 2) Bristol Stool Scale (BSS) score of 3 or 4 on 66% of reported days in the past week. Abdominal pain was assessed on an 11-point scale where: 0=no pain to 10=worst pain imaginable. Stool consistency was assessed using the BSS 7-point scale where: 1=separate hard lumps, 2=sausage shaped but lumpy, 3=sausage-like with cracks on the surface, 4=sausage-like but smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, and 7=watery with no solid pieces. Baseline (Week prior to Randomization) to Week 4
Primary Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores at Week 12 Composite responders were defined as participants who completed at least 5 out of 7 days with diary entries during the interval of interest and met both of the following criteria: 1) Average daily pain response scores over the past week improved by =30% and at least 2 points as compared with the baseline average pain score (average of daily worst abdominal pain the week prior to randomization), 2) Bristol Stool Scale (BSS) score of 3 or 4 on 66% of reported days in the past week. The participant recorded their abdominal pain in a daily diary using an 11-point scale where: 0=no pain to 10=worst pain imaginable. The participant recorded stool consistency in a daily diary using the BSS 7-point scale where: 1=separate hard lumps, 2=sausage shaped but lumpy, 3=sausage-like with cracks on the surface, 4=sausage-like but smooth and soft, 5=soft blobs with clear cut edges, 6=fluffy pieces with ragged edges, and 7=watery with no solid pieces. Baseline (Week prior to Randomization) to Week 12
Secondary Change From Baseline in the Weekly Pain Scores The participant recorded their worst daily pain score in a diary using an 11-point scale where: 0=no pain to 10=worst pain imaginable. The daily scores over the previous week were averaged. A negative change from Baseline indicates improvement. Baseline (Week Prior to Randomization) to Weeks 4, 8, and 12
Secondary Change From Baseline in Weekly BSS Scores The patient recorded stool consistency in a daily diary using the BSS 7-point scale where: 1=hard stool to 7=watery diarrhea. The daily scores over the previous week were averaged. A negative change from Baseline indicates improvement. Baseline (Week prior to Randomization) to Weeks 4, 8, and 12
Secondary Change From Baseline in the Number of Daily Bowel Movements Participants recorded the number of bowel movements in a daily diary at the same time each day. The number of daily bowel movements over the previous week were averaged. A negative change from Baseline indicates improvement. Baseline (Week prior to Randomization) to Weeks 4, 8, and 12
Secondary Percentage of Participants With Response Based on Participants Achieving Prespecified Improvement in Symptoms for at Least 50% of the Time Responders were participants that met both of the following criteria on the same week for at least 50% of time on study: 1) average of daily pain scores over the past week improved by =30% compared with baseline average in pain score, 2) =50% reduction in the number of days over the past week with a BSS score =5 compared with Baseline. Participants must also have had at least 5/7 days diary entry to be considered a responder for that week. Abdominal pain was assessed on an 11-point scale where a score of 0=no pain to 10=worst pain imaginable. Stool consistency was assessed using the BSS 7-point scale where: 1=separate hard lumps to 7=watery with no solid pieces. Response rates (percentage of participants) are based on model estimates from the logistic regression. Baseline (Week Prior to Randomization) to Weeks 1-12
See also
  Status Clinical Trial Phase
Completed NCT03720314 - Microbiota Profiling in IBS
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT05213910 - Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains N/A
Recruiting NCT05985018 - Traditional Dietary Advice Vs. Mediterranean Diet in IBS N/A
Completed NCT04486469 - Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study. N/A
Completed NCT06407609 - Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS N/A
Completed NCT04656730 - Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas Phase 4
Completed NCT04145856 - Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico Phase 4
Recruiting NCT04138225 - The Ecological Role of Yeasts in the Human Gut
Active, not recruiting NCT03586622 - One Year Home Monitoring and Treatment of IBS Patients N/A
Completed NCT05207618 - Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant N/A
Not yet recruiting NCT06369753 - Visible Abdominal Distension N/A
Not yet recruiting NCT05157867 - In Vivo Effects of Amylase Trypsin Inhibitors N/A
Not yet recruiting NCT05100719 - The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION) N/A
Recruiting NCT05001997 - Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome N/A
Recruiting NCT02953171 - Probiotics in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03266068 - Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
Completed NCT02977975 - Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome N/A
Completed NCT03318614 - Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster Phase 2/Phase 3
Completed NCT02980406 - The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level N/A